Shares of GlaxoSmithKline Pharmaceuticals surged 5.26% to Rs 2,724.90 in Wednesday's session, driven by high volume and an unusual surge in trading activity. The stock's movement was notable as it experienced a significant jump in volume, signalling increased investor interest and activity.
On the financial front, GlaxoSmithKline Pharmaceuticals has demonstrated consistent performance. The consolidated revenue for the year-ending March 2025 stood at Rs 3,749.21 Crore, up from Rs 3,453.71 Crore in the previous year. Net profit also saw a substantial increase, reaching Rs 927.58 Crore for the year-ending March 2025 compared to Rs 589.96 Crore in the year-ending March 2024.
| Heading | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,925.60 Crore | Rs 3,278.03 Crore | Rs 3,251.72 Crore | Rs 3,453.71 Crore | Rs 3,749.21 Crore |
| Net Profit | Rs 287.27 Crore | Rs 380.77 Crore | Rs 607.64 Crore | Rs 589.96 Crore | Rs 927.58 Crore |
| EPS | Rs 31.35 | Rs 99.29 | Rs 36.08 | Rs 41.14 | Rs 54.52 |
| BVPS | Rs 87.26 | Rs 157.19 | Rs 102.79 | Rs 104.93 | Rs 115.19 |
| ROE | 24.22 | 63.64 | 35.41 | 33.42 | 47.67 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
The company’s quarterly performance also reflects positive momentum. The consolidated revenue for the quarter-ending June 2025 was Rs 805.17 Crore, while the net profit stood at Rs 205.01 Crore. The Earnings Per Share (EPS) for the same period was Rs 12.10.
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 814.65 Crore | Rs 1,010.77 Crore | Rs 949.42 Crore | Rs 974.37 Crore | Rs 805.17 Crore |
| Net Profit | Rs 182.33 Crore | Rs 252.50 Crore | Rs 229.88 Crore | Rs 262.87 Crore | Rs 205.01 Crore |
| EPS | Rs 10.76 | Rs 14.91 | Rs 13.57 | Rs 15.52 | Rs 12.10 |
GlaxoSmithKline Pharmaceuticals is included as one of the stocks in the benchmark NIFTY MIDCAP 150 index.
Recent corporate actions include announcements regarding analyst/investor meets and disclosures under Regulation 30. The company announced a final dividend of Rs 42 per share on May 13, 2025, with an effective date of May 30, 2025. Additionally, a bonus issue was announced on July 24, 2018, with a bonus ratio of 1:1 and an ex-bonus date of September 11, 2018.
The stock's surge occurred amid a Moneycontrol analysis that pointed towards a bearish sentiment as of August 6, 2025.
With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session, driven by high trading volumes and positive financial performance.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
